시장보고서
상품코드
1431793

세계의 백신 시장(2024년)

The World Market for Vaccines, 2024

발행일: | 리서치사: Kalorama Information | 페이지 정보: 영문 202 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

백신은 질병에 대한 장기적이고 지속적인 면역력을 제공합니다. 백신은 70년 이상 예방 의학의 기초가 되어 왔으며, 특정 질병에 대한 면역 반응을 자극합니다. 효과적인 백신이 널리 보급되면서 많은 치명적인 질병이 거의 근절되었고, 백신 접종은 20세기 공중보건의 가장 큰 성과 중 하나가 되었습니다.

공공 예방접종 프로그램 덕분에 백신으로 예방할 수 있는 질병과 관련 사망은 선진국에서 드물어지고 전 세계적으로 감소하고 있습니다. 천연두는 근절되었고, 소아마비는 북미와 남미에서 퇴치되었으며, 홍역, 풍진, 파상풍, 디프테리아, 인플루엔자 B형 등의 질병은 억제되었습니다. 백신은 질병과 사망을 예방할 뿐만 아니라 삶의 질과 생산성을 향상시킵니다. 질병 발생을 예방하고 의료 비용을 절감하여 사회적으로 큰 이익을 가져왔습니다.

이 보고서는 세계 백신 시장을 조사했으며, 성인 및 소아 예방 백신에 대한 최신의 종합적인 분석을 제공합니다. 백신 카테고리별 시장 예측, 기업 점유율 데이터, 전문가 시장 예측, 다양한 질병 예방에 사용되는 인체용 백신 시장 동향도 조사했습니다. 특히 백신으로 예방할 수 있는 질병에 대해 이미 상용화된 백신과 개발 중인 백신 모두에 초점을 맞추었습니다.

목차

제1장 주요 요약

제2장 백신 서론

  • 서론
  • 간략한 역사 : 백신 개발
  • 인체 면역 체계
  • 백신 작용기전
  • 백신 유형
  • 약독화(약화) 생바이러스
  • 사멸한(비활성화) 바이러스
  • 톡소이드 백신
  • 유전자 재조합/변형 백신
  • 아단위 백신
  • 결합 백신
  • DNA 백신
  • 메신저 RNA 백신
  • 재조합 벡터 백신
  • 백신 분류
  • 백신 승인 프로세스
  • FDA EUA 승인
  • 세계보건기구 사전 적격성 평가 백신
  • 팬데믹
  • HIN1 2009/2010년 팬데믹
  • 코로나바이러스 팬데믹
  • 에볼라 출혈열의 유행
  • 제조 인센티브
  • 합성 백신
  • 인공지능 개발

제3장 소아 예방 백신

  • 서론
  • 미국의 아동 예방 접종
  • 아동 예방 접종률
  • 백신 전달 시스템의 과제
  • 권장 아동 예방 접종 일정
  • 주별 예방 접종 추천 사항
  • COVID-19 예방 접종 일정
  • 유엔의 이니셔티브
  • 소아 백신 시장
  • 경쟁 개요

제4장 성인 예방 백신

  • 서론
  • 권장 성인 예방 접종
  • 세계의 인플루엔자 감시 프로그램
  • 미국의 감시
  • WHO의 국제 보건 규칙
  • 성인 예방 백신 시장
  • 시장 : 시장 전체 성인용 비코비드 백신 매출의 26% 창출
  • 인플루엔자
  • 경쟁 개요

제5장 백신 시장 전체

  • 백신 시장 성장을 촉진하는 동향
  • 시장 규모와 예측
  • 소아용 백신
  • 성인용 백신
  • COVID-19 시장 규모 추정 및 예측
  • 지역별 백신 판매량
  • 세계 기타 지역
  • 미국
  • 유럽
  • 백신 시장의 경쟁사
  • 백신 업계 뉴스
  • 개발 중인 백신
  • COVID-19 백신 개발

제6장 기업 개요

  • AstraZeneca
  • Bavarian Nordic, A/S
  • Bharat Biotech International Ltd.
  • Bio Farma
  • BioNTech SE
  • CSL Limited/Seqirus
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson/Crucell/Janssen
  • Merck & Co, Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi Pasteur
  • Serum Institute, Inc.
  • Sinovac Biotech Ltd.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Co, Ltd.
  • Valneva SE
LSH 24.03.05

Vaccines offer long-term or permanent immunity against diseases. They have been a cornerstone of preventive medicine for over 70 years, stimulating an immune response to specific diseases. The widespread adoption of effective vaccines has led to the near-elimination of many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century.

Thanks to public vaccination programs, vaccine-preventable diseases and related deaths are now rare in developed nations and decreasing globally. Smallpox has been eradicated, polio eliminated in the Americas, and diseases like measles, rubella, tetanus, diphtheria, and Haemophilus influenzae type b controlled. Beyond preventing illness and death, vaccines also improve quality of life and productivity. They help prevent disease outbreaks and reduce healthcare costs, providing significant societal benefits.

Kalorama Information's latest report, "The World Market for Vaccines, 2024", offers the most up-to-date and comprehensive analysis of adult and pediatric preventative vaccines. Since the early 2000s, Kalorama has consistently published new editions of The World Market for Vaccines every two years. The report includes market forecasts, company market share data, and expert market estimates for different vaccine categories.

"The World Market for Vaccines, 2024" also examines market trends for human vaccines used to prevent various diseases. It specifically focuses on both commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Additionally, the report discusses selected emerging vaccines in development.

Vaccines covered in the report with sizing and market share include:

  • Combinations (tetanus, pertussis, Hib, Hepatitis, polio)
  • Hepatitis
  • HPV
  • Influenza
  • Meningitis
  • Pandemic vaccines/COVID-19
  • Pneumococcal
  • Rotavirus
  • RSV
  • Shingles
  • Others (travel, endemic, etc.)

The report also examines key companies involved in the market. Companies profiled in the report include:

  • AstraZeneca
  • Bavarian Nordic, A/S
  • Bharat Biotech International Ltd.
  • Bio Farma
  • BioNTech SE
  • CSL Limited/Seqirus
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson/Crucell/Janssen
  • Merck & Co, Inc.
  • Moderna, Inc
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi Pasteur
  • Serum Institute, Inc.
  • Sinovac Biotech Ltd.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Co, Ltd.
  • Valneva SE

Scope and Methodology

"The World Market for Vaccines, 2024" examines the market for human vaccines used to prevent various types of disease. It focuses on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of selected emerging vaccines. It also covers the COVID-19 vaccine market landscape and estimated market opportunity during the forecast period. This report does not include therapeutic vaccines such as allergy and cancer vaccines.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the 2023 year and forecasts are provided for 2028. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts' reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants' point of view and assess trends and form the basis of the forecasting and competitive analysis.

It should also be noted that due to the very broad scope of this report, with the exception of healthcare spending forecasts, data provided is representative but is not intended to be exhaustive. This includes, for example, tables of vaccines in development and regional economic indicators, etc. Additionally, some statistics, such as those related to venture capital investment, are subject to wide divergences across different sources; where data could not be confidently obtained, trends were discussed rather than absolute numerical values.

Table of Contents

Chapter 1: Executive Summary

  • The Global Vaccines Industry
  • Scope and Methodology
  • Market Estimates and Forecasts
    • Figure 1-1: Global Vaccine Market (Non-COVID Vaccine Market; COVID Vaccine Market), 2023-2028 ($M)
    • Figure 1-2: Regional Non-COVID vs COVID Vaccine Markets, 2018-2028 ($)
  • Competitive Analysis

Chapter 2: Introduction to Vaccines

  • Introduction
    • Table 2-1: Global Reported Cases of Vaccine Preventable Diseases, 2000 vs. 2022
    • Figure 2-1: CDC Infographic: Global Impact of Vaccines in Reducing Vaccine-Preventable Disease Morbidity and Mortality
  • A Brief History: The Development of Vaccines
  • The Human Immune System
  • Vaccine Mechanism of Action
  • Types of Vaccines
  • Attenuated (Weakened) Live Viruses
    • Figure 2-2: Attenuated Virus Production
  • Killed (Inactivated) Viruses
  • Toxoid Vaccines
  • Genetically Engineered/Modified Vaccines
  • Subunit Vaccines
  • Conjugate Vaccines
  • DNA Vaccines
  • Messenger RNA Vaccines
  • Recombinant Vector Vaccines
  • Classification of Vaccines
  • Vaccine Approval Process
    • Figure 2-3: Global Vaccine Sales by Region, 2023
  • FDA EUA Approval
  • World Health Organization Prequalified Vaccines
    • Table 2-3: WHO Prequalified BCG Vaccines
    • Table 2-4: WHO Prequalified Cholera Vaccines
    • Table 2-5: WHO Prequalified Diphtheria-Tetanus Vaccines
    • Table 2-6: WHO Prequalified Diphtheria-Tetanus-Pertussis Vaccines
    • Table 2-7: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hemophilus influenzae type b Vaccines
    • Table 2-8: WHO Prequalified Diphtheria-Tetanus-Pertussis and Hepatitis B Vaccines
    • Table 2-9: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hepatitis B-Hemophilus influenzae type b Vaccines
    • Table 2-10: WHO Prequalified Hemophilus influenzae type b Vaccines
    • Table 2-11: WHO Prequalified Hepatitis A Vaccines
    • Table 2-12: WHO Prequalified Hepatitis B Vaccines
    • Table 2-13: WHO Prequalified Human Papillomavirus Vaccines
    • Table 2-14: WHO Prequalified Influenza Vaccines
    • Table 2-15: WHO Prequalified Japanese Encephalitis Vaccines
    • Table 2-16: WHO Prequalified Measles Vaccines
    • Table 2-17: WHO Prequalified Measles and Rubella Vaccines
    • Table 2-18: WHO Prequalified Measles, Mumps and Rubella Vaccines
    • Table 2-19: WHO Prequalified Meningococcal A Vaccines
    • Table 2-20: WHO Prequalified Pneumococcal Vaccines
    • Table 2-21: WHO Prequalified Polio Vaccines
    • Table 2-22: WHO Prequalified Rabies Vaccines
    • Table 2-23: WHO Prequalified Rotavirus Vaccines
    • Table 2-24: WHO Prequalified Rubella Vaccines
    • Table 2-25: WHO Prequalified Tetanus Toxoid Vaccines
    • Table 2-26: WHO Prequalified Typhoid Vaccines
    • Table 2-27: WHO Prequalified Varicella Vaccine
    • Table 2-28: WHO Prequalified Yellow Fever Vaccines
    • Table 2-29: WHO Prequalified Other Vaccines
  • Pandemics
  • HIN1 Pandemic of 2009/2010
  • Coronavirus Pandemic
    • Figure 2-4: Leading COVID-19 Vaccines: Supplied Dose Estimates
  • Ebola Epidemics
  • Manufacturing Incentives
  • Synthetic Vaccines
  • Artificial Intelligence Development

Chapter 3: Pediatric Preventative Vaccines

  • Introduction
    • Table 3-1: Immunization Rates for Vaccines Recommended by the WHO, 2022
  • Childhood Immunization in the United States
  • Childhood Immunization Rates
  • Challenges to the Vaccine Delivery System
  • Recommended Childhood Immunization Schedule
    • Figure 3-1: CDC Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024
    • Figure 3-2: CDC Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2024
  • State Immunization Recommendations
    • Figure 3-3: Exemptions Permitted for State Childcare and School (Grades PreK-12) Immunization Requirements, United States, March 2023
  • COVID-19 Vaccination Schedule
  • United Nations Initiatives
  • Pediatric Vaccine Markets
    • Table 3-2: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023-2028 ($M)
    • Figure 3-4: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023-2028 (%)
    • Figure 3-5: Market Share of Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023 (%)
  • Competitive Summary
    • Table 3-3: Major Manufacturers' Shares of the Global Pediatric Preventative Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
    • Figure 3-6: Global Pediatric Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023, (%)

Chapter 4: Adult Preventative Vaccines

  • Introduction
  • Recommended Adult Immunizations
    • Figure 4-1: CDC Recommended Immunization Schedule: Adults, 19 years and over
  • Global Influenza Surveillance Program
  • U.S. Surveillance
    • Table: 4-1: U.S. Influenza Vaccine Effectiveness, 2004-2023 (%)
    • Figure 4-2: U.S. Influenza Vaccine Effectiveness, by Season, 2009-2023, (%)
  • WHO International Health Regulations
  • Adult Preventive Vaccine Markets
    • Table 4-2: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023-2028 ($M)
    • Figure 4-3: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other), 2023-2028 (%)
    • Figure 4-4: Market Share of Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023 (%)
  • Market: Generating 26% of Total Adult Non-COVID Vaccine Sales
    • Figure 4-5: U.S. Seasonal Influenza Vaccination, by Age Group and Season, 2010-2023 (%)
    • Figure 4-6: U.S. Seasonal Influenza Vaccination Coverage and HP 2020 Target - Total Population - Seasons, 2010-2023 (%)
  • Influenza
    • Figure 4-7: Estimated U.S. Flu Burden, by Season 2010-2023
    • Table 4-3: Estimated Number of Influenza Illnesses Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-4: Estimated Number of Influenza Medical Visits Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-5: Estimated Number and Fraction of Influenza Hospitalizations Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-6: Estimated Number of Influenza Deaths Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Figure 4-8: Estimated U.S. Flu Burden Prevented by Vaccination (Deaths, Hospitalizations, Medical Visits, Symptomatic Illness), 2010-2023
    • Table 4-7: WHO Pandemic Classification Schedule
  • Competitive Summary
    • Table 4-8: Major Manufacturers' Shares of the Global Adult Preventative Vaccine Market, by Company (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
    • Figure 4-9: Global Adult Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%)

Chapter 5: Total Vaccines Market

  • Trends Driving the Vaccines Market
    • Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals, 2015-2025
  • Market Size and Forecast
    • Table 5-1: Total Global Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
    • Figure 5-2: Total World Market for Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]),, 2023-2028 (Pediatric, Adult) (SM)
    • Figure 5-3: Total World Vaccine Market, Non-COVID and COVID Vaccine, 2023-2028 ($M)
  • Pediatric Vaccines
  • Adult Vaccines
    • Figure 5-4: Global Preventive Vaccine Market, by Broad Segment (Pediatric, Adult), Trend 2018-2028 ($M)
  • COVID-19 Market Size Estimates and Forecast
    • Table 5-2: Global COVID-19 Vaccine Market Cumulative Value, 2020-2023 ($M)
    • Figure 5-5: Global COVID-19 Vaccine by Unit Volume, Cumulative 2020-2023, Estimated Distribution by Country (Australia, Brazil, Canada, China, European Union, India, Japan, Russia, South Africa, South Korea, United States, Other Countries)
  • Vaccine Sales by Region
  • Rest of World
    • Table 5-3: Total ROW Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • United States
    • Table 5-4: Total U.S. Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • Europe
    • Table 5-5: Total Europe Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • Vaccine Market Competitors
    • Table 5-6: Major Manufacturers' Shares of the Global Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%, $M)
    • Figure 5-6: Global Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%)
  • Vaccine Industry News
  • Vaccines in Development
  • COVID-19 Vaccine Development
    • Figure 5-7: Regional Distribution of COVID-19 Vaccine Development, by Country and Region (Australia, Brazil, Canada, China, France, Indonesia, Japan, Mexico, Middle East, Philippines, Rest of Africa, Rest of Pacific, Rest of Europe, Rest of Latin America, South Africa, South Korea, United Kingdom, United States)
    • Table 5-7: Selected Vaccines in Development, 2023

Chapter 6: Company Profiles

  • AstraZeneca
    • Table 6-1: AstraZeneca Corporate Summary
      • Company Summary
      • Products
  • Bavarian Nordic, A/S
    • Table 6-2: Bavarian Nordic A/S Corporate Summary
      • Company Summary
      • Products
  • Bharat Biotech International Ltd.
    • Table 6-3: Bharat Biotech Corporate Summary
      • Company Summary
      • Products
  • Bio Farma
    • Table 6-4: Bio Farma Corporate Summary
      • Company Summary
      • Products
  • BioNTech SE
    • Table 6-5: BioNTech Corporate Summary
      • Company Summary
      • Products
  • CSL Limited/Seqirus
    • Table 6-6: CSL/Seqirus Corporate Summary
      • Company Summary
      • Products
  • Dynavax Technologies
    • Table 6-7: Dynavax Technologies Corporate Summary
      • Company Summary
      • Products
  • Emergent BioSolutions, Inc.
    • Table 6-8: Emergent BioSolutions Corporate Summary
      • Company Summary
      • Products
  • GlaxoSmithKline, Inc.
    • Table 6-9: GlaxoSmithKline Corporate Summary
      • Company Summary
      • Products
    • Table 6-10: GSK Marketed Vaccines, 2024
  • Inovio Pharmaceuticals, Inc.
    • Table 6-11: Inovio Corporate Summary
      • Company Summary
      • Products
  • Johnson & Johnson/Crucell/Janssen
    • Table 6-12: Johnson & Johnson Corporate Summary
      • Company Summary
      • Products
  • Merck & Co, Inc.
    • Table 6-13: Merck Corporate Summary
      • Company Summary
      • Products
  • Moderna, Inc.
    • Table 6-14: Moderna Corporate Summary
      • Company Summary
      • Products
  • Novavax, Inc.
    • Table 6-15: Novavax Corporate Summary
      • Company Summary
      • Products
  • Pfizer, Inc.
    • Table 6-16: Pfizer Corporate Summary
      • Company Summary
      • Products
  • Sanofi Pasteur
    • Table 6-17: Sanofi Pasteur Corporate Summary
      • Company Summary
      • Products
  • Serum Institute, Inc.
    • Table 6-18: Serum Institute of India Corporate Summary
      • Company Summary
      • Products
  • Sinovac Biotech Ltd.
    • Table 6-19: Sinovac Biotech Corporate Summary
      • Company Summary
      • Products
  • Soligenix, Inc.
    • Table 6-20: Soligenix Corporate Summary
      • Company Summary
      • Products
  • Takeda Pharmaceutical Co, Ltd.
    • Table 6-21: Takeda Pharmaceutical Corporate Summary
      • Company Summary
      • Products
  • Valneva SE
    • Table 6-22: Valneva Corporate Summary
      • Company Summary
      • Products
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제